This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

Artelac

OTC
Read time: 1 mins
Last updated: 06 Oct 2015

Summary of product characteristics


1. Name of the medicinal product

Artelac 0.32% w/v Eye Drops Single Dose Unit


2. Qualitative and quantitative composition

Hypromellose, 0.32% w/vFor full list of excipients, see 6.1.


3. Pharmaceutical form

Eye drops, solution in single-dose container.Sterile clear solution


4.1. Therapeutic indications

This medicinal product acts as a lubricant and artificial tear in the symptomatic treatment of dehydration of the cornea and conjunctiva due to impaired lacrimal secretion and functional disorders as a result of topical or systemic diseases, or caused by deficient or incomplete eyelid closure.Artelac 0.32% w/v Eye Drops Single Dose Unit is indicated in adults and children.


4.2. Posology and method of administration

Posology

Suitable for use in adults and children.Unless otherwise directed, instill 1 drop into the conjunctival sac (corner of the eye, nearest the nose) 3 to 5 times per day or as required, to provide sufficient lubrication.Therapy of dry eye syndrome requires an individual dosage regimen.Leave an interval of at least 5 minutes before instilling another ophthalmic medication

Method of administration

For ocular use only


4.3. Contraindications

Hypersensitivity to the active substance (hypromellose) or to any of the excipients listed in section 6.1.


4.4. Special warnings and precautions for use

Stop treatment and consult a physician if irritation persists or worsens or new eye signs or symptoms develop. Wearers of soft contact lenses should remove their lenses before Artelac 0.32% w/v Eye Drops Single Dose Unit is administered and should wait for at least 15 minutes before they insert them again.


4.5. Interaction with other medicinal products and other forms of interaction

None


4.6. Fertility, pregnancy and lactation

Pregnancy

Artelac 0.32% w/v Eye Drops Single Dose Unit can be used during pregnancy

Breast-feeding

Artelac 0.32% w/v Eye Drops Single Dose Unit can be used in lactation.

Fertility

Artelac 0.32% w/v Eye Drops Single Dose Unit is not expected to have any effect on fertility.


4.7. Effects on ability to drive and use machines

Artelac 0.32% w/v Eye Drops Single Dose Unit on instillation may cause a short term blurring of vision when first used. If affected wait until vision has cleared before driving or operating machinery.


4.8. Undesirable effects

The following adverse reactions have been reported following administration of Artelac 0.32% w/v Eye Drops Single Dose Unit.

Eye disorder:

Very rare (<1/10,000):Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.

Not known:

Brief blurred vision or a slight stinging sensation on instilling Artelac 0.32% w/v Eye Drops Single Dose Unit.Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard


4.9. Overdose

No case of overdose has been reported.


5.1. Pharmacodynamic properties

Pharmacotherapeutic group:Ophthalmologicals: other ophthalmologicalsATC code: S01X A20Hypromellose prolongs adhesion, enhances moistening of the cornea and conjunctiva and allows for a smoother movement of the conjunctiva over the cornea.


5.2. Pharmacokinetic properties

Hypromellose does not permeate the cornea or reach the systemic circulation via the ophthalmic vessels.


5.3. Preclinical safety data

There is no preclinical data of relevance to the prescriber.


6.1. List of excipients

Disodium phosphate dodecahydrateSodium dihydrogen phosphate dihydrateSorbitolPurified water


6.2. Incompatibilities

Not applicable


6.3. Shelf life

2 years


6.4. Special precautions for storage

Do not store above 25°C.


6.5. Nature and contents of container

0.5 ml single dose unit, composed of LDPE.30, 60 and 120 single dose units


6.6. Special precautions for disposal and other handling

Avoid contamination during use. Artelac SDU eye drops are sterile until first opened.For single use only. Each carton contains a patient insert with instructions for use.


7. Marketing authorisation holder

Bausch & Lomb (UK) LtdBausch &Lomb House106 London RoadKingston-Upon-ThamesSurrey KT2 6TNUK


8. Marketing authorisation number(s)

PL 03468/0033


9. Date of first authorisation/renewal of the authorisation

16/09/2010


10. Date of revision of the text

15/05/2015

4.1 Therapeutic indications

This medicinal product acts as a lubricant and artificial tear in the symptomatic treatment of dehydration of the cornea and conjunctiva due to impaired lacrimal secretion and functional disorders as a result of topical or systemic diseases, or caused by deficient or incomplete eyelid closure.Artelac 0.32% w/v Eye Drops Single Dose Unit is indicated in adults and children.

4.2 Posology and method of administration

Posology

Suitable for use in adults and children.Unless otherwise directed, instill 1 drop into the conjunctival sac (corner of the eye, nearest the nose) 3 to 5 times per day or as required, to provide sufficient lubrication.Therapy of dry eye syndrome requires an individual dosage regimen.Leave an interval of at least 5 minutes before instilling another ophthalmic medication

Method of administration

For ocular use only

4.3 Contraindications

Hypersensitivity to the active substance (hypromellose) or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Stop treatment and consult a physician if irritation persists or worsens or new eye signs or symptoms develop. Wearers of soft contact lenses should remove their lenses before Artelac 0.32% w/v Eye Drops Single Dose Unit is administered and should wait for at least 15 minutes before they insert them again.

4.5 Interaction with other medicinal products and other forms of interaction

None

4.6 Fertility, pregnancy and lactation

Pregnancy

Artelac 0.32% w/v Eye Drops Single Dose Unit can be used during pregnancy

Breast-feeding

Artelac 0.32% w/v Eye Drops Single Dose Unit can be used in lactation.

Fertility

Artelac 0.32% w/v Eye Drops Single Dose Unit is not expected to have any effect on fertility.

4.7 Effects on ability to drive and use machines

Artelac 0.32% w/v Eye Drops Single Dose Unit on instillation may cause a short term blurring of vision when first used. If affected wait until vision has cleared before driving or operating machinery.

4.8 Undesirable effects

The following adverse reactions have been reported following administration of Artelac 0.32% w/v Eye Drops Single Dose Unit.

Eye disorder:

Very rare (<1/10,000):Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.

Not known:

Brief blurred vision or a slight stinging sensation on instilling Artelac 0.32% w/v Eye Drops Single Dose Unit.Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).